{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:20:09Z","timestamp":1795101609365,"version":"4.10.3"},"reference-count":38,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Factor VIII (FVIII) replacement remains central to the management of hemophilia A. Extended half-life (EHL)\u2013FVIII concentrates, developed through Fc-fusion or PEGylation, extend terminal half-life and overall exposure area under the curve (AUC) by \u223c30% compared with standard half-life (SHL) products but remain limited by the von Willebrand factor (VWF)\u2013imposed half-life ceiling. A newly engineered high-sustained-activity\/ultralong half-life FVIII (HSA\/UL-FVIII) eliminates VWF binding through multiple structural modifications, achieving a fourfold longer half-life, a sixfold greater AUC than SHL-FVIII, and FVIII activity within the nonhemophilia range for several days following once-weekly dosing. Using population pharmacokinetic (PK) modeling, we simulated single-dose and steady-state FVIII activity-time profiles in 1000 virtual patients treated with SHL-, EHL-, or HSA\/UL-FVIII. Time spent and area above clinically relevant FVIII thresholds clearly differentiated HSA\/UL-FVIII from EHL products. These data support updating FVIII product classification and highlight the value of new PK-based metrics, including time-above-threshold and segmented AUC, in evaluating next-generation FVIII therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019054","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:54:11Z","timestamp":1770936851000},"page":"3409-3417","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["A revised classification of FVIII concentrates: rationale and novel metrics"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[{"name":"1Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Universit\u00e9 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, United Kingdom"},{"name":"3Department of Haematology, Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-8797","authenticated-orcid":false,"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[{"name":"4Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[{"name":"5Department of Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-7098","authenticated-orcid":false,"given":"Axel","family":"Facius","sequence":"additional","affiliation":[{"name":"6thinkQ2 AG, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-4028","authenticated-orcid":false,"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[{"name":"7Department of Biomedical Sciences, Humanitas University, Milan, Italy"},{"name":"8Center for Thrombosis and Hemorrhagic Diseases, Humanitas Research Hospital Istituti di Ricovero e Cura a Carattere Scientifico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"10480","key":"2026052610371748500_bib1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"2026052610371748500_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"10274","key":"2026052610371748500_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2026052610371748500_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"issue":"3","key":"2026052610371748500_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026052610371748500_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-0044-1791778","article-title":"Factor replacement treatment for hemophilia A: achievements and perspectives","volume":"51","author":"Mancuso","year":"2025","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"2026052610371748500_bib7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level?","volume":"27","author":"Collins","year":"2021","journal-title":"Haemophilia"},{"issue":"10","key":"2026052610371748500_bib8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17474086.2024.2402304","article-title":"Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies","volume":"17","author":"Mahlangu","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"2026052610371748500_bib9","first-page":"239","article-title":"Current understanding of inherited modifiers of FVIII pharmacokinetic variation","volume":"16","author":"Swystun","year":"2023","journal-title":"Pharmgenomics Pers Med"},{"issue":"5","key":"2026052610371748500_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/rth2.12335","article-title":"Development of inhibitors in hemophilia A: an illustrated review","volume":"4","author":"Jardim","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2026052610371748500_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jth.12161","article-title":"Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A","volume":"11","author":"Tiede","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026052610371748500_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/jth.12506","article-title":"Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A","volume":"12","author":"Coyle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026052610371748500_bib13","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2026052610371748500_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2026052610371748500_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13438","article-title":"Defining extended half-life rFVIII-A critical review of the evidence","volume":"24","author":"Mahlangu","year":"2018","journal-title":"Haemophilia"},{"key":"2026052610371748500_bib16","doi-asserted-by":"crossref","first-page":"2040620720966888","DOI":"10.1177\/2040620720966888","article-title":"Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities-a practical review","volume":"11","author":"Hermans","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2026052610371748500_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0038-1646423","article-title":"The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII\/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis","volume":"66","author":"Morfini","year":"1991","journal-title":"Thromb Haemost"},{"issue":"1","key":"2026052610371748500_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/hae.14691","article-title":"Area under the curve: comparing the value of factor VIII replacement therapies in haemophilia A","volume":"29","author":"Persson","year":"2023","journal-title":"Haemophilia"},{"issue":"2","key":"2026052610371748500_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/rth2.12305","article-title":"Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes","volume":"4","author":"Croteau","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"2026052610371748500_bib20","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/ejh.13610","article-title":"Recombinant factor VIII Fc for the treatment of haemophilia A","volume":"106","author":"Hermans","year":"2021","journal-title":"Eur J Haematol"},{"issue":"3","key":"2026052610371748500_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40268-024-00481-7","article-title":"Damoctocog alfa pegol, a PEGylated B-domain deleted recombinant extended half-life factor VIII for the treatment of hemophilia A: a product review","volume":"24","author":"Reding","year":"2024","journal-title":"Drugs R D"},{"issue":"4","key":"2026052610371748500_bib22","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/hae.14052","article-title":"Long-term safety and efficacy results from the phase 3b, open-label, multicentre continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A","volume":"26","author":"Chowdary","year":"2020","journal-title":"Haemophilia"},{"key":"2026052610371748500_bib23","doi-asserted-by":"crossref","first-page":"103678","DOI":"10.1016\/j.critrevonc.2022.103678","article-title":"Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician\u2019s perspective","volume":"174","author":"Hermans","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"2026052610371748500_bib24","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026052610371748500_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"2026052610371748500_bib26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026052610371748500_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A","volume":"383","author":"Konkle","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"2026052610371748500_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.2020005250","article-title":"A molecular jewel for hemophilia A treatment","volume":"135","author":"Rayes","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026052610371748500_bib29","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.rpth.2023.100176","article-title":"Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa","volume":"7","author":"Lissitchkov","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026052610371748500_bib30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2026052610371748500_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40262-019-00809-6","article-title":"Development and validation of a population-pharmacokinetic model for rurioctacog alfa pegol (Adynovate\u00ae): a report on behalf of the WAPPS-hemo investigators Ad Hoc subgroup","volume":"59","author":"Chelle","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"2026052610371748500_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/jcph.1854","article-title":"Population pharmacokinetic analysis of recombinant factor VIII Fc fusion protein in subjects with severe hemophilia A: expanded to include pediatric subjects","volume":"61","author":"Katragadda","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"suppl 1","key":"2026052610371748500_bib33","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1182\/blood-2022-167483","article-title":"A population pharmacokinetic (PopPK) model to characterize efanesoctocog alfa (BIVV001) factor VIII (FVIII) activity levels in patients with severe hemophilia A","volume":"140","author":"Bhagunde","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2026052610371748500_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/hae.12605","article-title":"Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling","volume":"21","author":"Gringeri","year":"2015","journal-title":"Haemophilia"},{"issue":"6","key":"2026052610371748500_bib35","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/hae.15091","article-title":"Determination of body composition by dual x-ray absorptiometry in persons with haemophilia","volume":"30","author":"Ransmann","year":"2024","journal-title":"Haemophilia"},{"key":"2026052610371748500_bib36","unstructured":"Sobi Science Library\n          . Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program. Accessed 10 March 2025. https:\/\/sciencelibrary.sobi.com\/efanesoctocog-alfa-perioperative-management-patients-severe-haemophilia-4-years-experience-xtend."},{"issue":"1","key":"2026052610371748500_bib37","first-page":"1","article-title":"Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A","volume":"116","author":"Mahlangu","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026052610371748500_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.08.023","article-title":"Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: results of the PROTECT VIII clinical trial","volume":"183","author":"Santagostino","year":"2019","journal-title":"Thromb Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3409\/2518701\/blooda_adv-2025-019054-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3409\/2518701\/blooda_adv-2025-019054-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:28Z","timestamp":1779806248000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3409\/566587\/A-revised-classification-of-FVIII-concentrates"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019054","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,13]]}}}